Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CEND-1 |
Synonyms | |
Therapy Description |
CEND-1 is a peptide that is targeted to tumors via interaction with alpha-integrins and potentially increases the delivery of other antitumor agents via interaction with neuropilin-1 (Annals of Oncology 31 (2020): S941). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CEND-1 | CEND1|CEND 1|LSTA 1|LSTA-1|LSTA1|iRGD | CEND-1 is a peptide that is targeted to tumors via interaction with alpha-integrins and potentially increases the delivery of other antitumor agents via interaction with neuropilin-1 (Annals of Oncology 31 (2020): S941). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06216561 | Phase I | CEND-1 | Intraperitoneal LSTA1 in CRS-HIPEC | Withdrawn | USA | 0 |